NEW YORK (GenomeWeb News) – China's BGI said it has purchased 37 of Life Technologies' Ion Proton next-generation sequencing systems and will add at least 12 more machines by the end of the year.

Additionally, Shenzhen, China-based BGI said it has signed a supply and licensing agreement with Life Tech.

BGI will use the Proton for exome and transcriptome sequencing, as well as aneuploidy testing, according to a statement. The institution has already validated the Proton's PI chip, delivering 80 million reads in two- to three-hour sequencing runs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.